Alkermes plc - Ordinary Shares (ALKS)
ALKS moved a median of -0.03% 30 minutes after news, and -0.12% by the close. How ALKS actually reacts to news — the realized, point-in-time move the market made, measured across 480 labeled events over the last three years with zero look-ahead.
ALKS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 479 |
| 30-min | -0.03% | 47% | 479 |
| 60-min | -0.16% | 46% | 479 |
| to close | -0.12% | 47% | 474 |
| Middle 50% of ALKS reactions | -0.61% to +0.60% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 480 |
Half of all Alkermes plc - Ordinary Shares news events land between -0.61% and +0.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALKS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 31 | -0.21% | 32% | -0.56% |
| Analyst downgrades | 17 | -0.31% | 35% | -0.69% |
| Coverage initiations | 37 | -0.07% | 49% | +0.77% |
| Rating reiterations | 98 | -0.00% | 49% | +0.35% |
| Price-target raises | 28 | -0.17% | 39% | +0.07% |
| Price-target cuts | 12 | +0.09% | 67% | +0.09% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ALKS ranks against every other measured name →
That’s how ALKS usually reacts — get an email when it moves on news →Email me when ALKS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALKS's baseline. Nothing else.
Recent ALKS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research | Press release | Business Wire | +0.21% | -1.32% | |
| Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) | Press release | Business Wire | -1.18% | -0.20% | |
| Form 8-K Alkermes plc. For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -0.20% | |
| Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors | Press release | Business Wire | +0.17% | -1.22% | |
| Form 8-K Alkermes plc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -1.22% | |
| Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program | Press release | Business Wire | +0.78% | +2.51% | |
| The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 | Press release | Business Wire | +1.36% | +0.70% | |
| Form 8-K Alkermes plc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | +2.15% | |
| Form 8-K/A Alkermes plc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | -0.12% | |
| Alkermes plc Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +3.06% | +0.36% | |
| Form 10-Q Alkermes plc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.06% | +0.36% | |
| Form 8-K Alkermes plc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +3.06% | +0.36% | |
| Form S-8 Alkermes plc. | SEC filing · Form S-8 | SEC EDGAR | +0.08% | -4.28% | |
| Alkermes to Report Second Quarter Financial Results on July 28, 2026 | Press release | Business Wire | -1.41% | +0.66% | |
| Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis | Press release | Business Wire | +0.33% | +1.57% | |
| Form 8-K Alkermes plc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -0.15% | |
| Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 | Press release | Business Wire | -0.46% | -0.77% | |
| Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | Press release | Business Wire | +0.08% | +1.12% | |
| Form 8-K Alkermes plc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +1.12% | |
| Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research | Press release | Business Wire | +1.79% | +0.77% | |
| Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +1.79% | +0.77% | |
| Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting | Press release | Business Wire | -0.42% | +1.50% | |
| Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences | Press release | Business Wire | -0.82% | +0.85% | |
| Form 8-K Alkermes plc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | +0.85% | |
| Form DEFA14A Alkermes plc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.23% | -1.26% | |
| Alkermes Announces Positive Topline Results From REVITALYZ? Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia | Press release | Business Wire | +0.94% | +6.36% | |
| Form 8-K Alkermes plc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | +6.36% | |
| Alkermes plc Reports First Quarter 2026 Financial Results | Press release | Business Wire | -1.60% | +2.84% | |
| Form 10-Q Alkermes plc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.45% | -2.73% | |
| Form 8-K Alkermes plc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | +2.84% | |
| Form 8-K/A Alkermes plc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +2.92% | |
| Alkermes to Report First Quarter Financial Results on May 5, 2026 | Press release | Business Wire | +0.58% | +0.66% | |
| Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting | Press release | Business Wire | +0.70% | +2.13% | |
| Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry | Press release | Business Wire | +0.83% | +0.41% | |
| Form ARS Alkermes plc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.96% | -2.48% | |
| Form DEF 14A Alkermes plc. For: May 20 | SEC filing · Form DEF | SEC EDGAR | -0.96% | -2.48% | |
| Form DEFA14A Alkermes plc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.96% | -2.48% | |
| Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 | Press release | Business Wire | +2.08% | -1.27% | |
| Form PRE 14A Alkermes plc. For: May 20 | SEC filing · Form PRE | SEC EDGAR | -0.31% | +2.59% | |
| Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program | Press release | Business Wire | -0.73% | +0.77% | |
| Alkermes to Present at the Stifel 2026 Virtual CNS Forum | Press release | Business Wire | +0.14% | +0.69% | |
| Alkermes plc Announces CEO Succession Plan | Press release | Business Wire | -2.09% | -4.49% | |
| Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 | Press release | Business Wire | -2.09% | -4.49% | |
| Form 10-K Alkermes plc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.23% | |
| Form 8-K Alkermes plc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | -3.15% | |
| Form 8-K Alkermes plc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.09% | -4.49% | |
| Alkermes to Present at the TD Cowen 46th Annual Health Care Conference | Press release | Business Wire | -2.09% | -4.49% | |
| Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market | Press release | Business Wire | +1.11% | -0.12% | |
| Form 8-K Alkermes plc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | -0.12% | |
| Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 | Press release | Business Wire | +1.11% | -0.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALKS section they belong to.
Where else ALKS is measured.
ALKS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | 482 | 0.00% | 50% |
| Medtronic plc. Ordinary Shares (MDT) | 481 | -0.06% | 45% |
| HCA Healthcare, Inc. (HCA) | 479 | +0.30% | 62% |
| NEOS THERAPEUTICS (NEOS) | 479 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alkermes plc - Ordinary Shares's median reaction calculated?
Every labeled ALKS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 480 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of ALKS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALKS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.